Clear Cell Sarcoma - Pipeline Insight, 2024

This “Clear Cell Sarcoma - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Clear Cell Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Clear Cell Sarcoma Understanding

Clear Cell Sarcoma: Overview

Clear-cell sarcoma (CCS) is a rare tumor and preferentially arises in soft tissue in the extremities, sometimes referred to as “melanoma of the soft parts” based on evidence of melanocytic differentiation of these cells. Clear cell sarcoma gets its name from the fact that the cells of the tumor look clear under a microscope. Clear cell sarcoma tumors tend to grow attached to tendons in the limbs, especially in the feet and hands. They sometimes develop in the gastrointestinal tract, attached with the bottom layers of the skin, and in locations throughout the torso. Clear cell sarcoma is slightly more common in females than in males and can occur at all age, the mean age at the time of diagnosis is approximately 25 years. CCS is distinguished from malignant melanoma by the presence of a specific fusion of an oncogene EWS/ATF1, which results from a reciprocal translocation.

Symptoms
The symptoms of Clear Cell Sarcoma include:

• Slow-growing lump
• Fatigue
• Weight loss
• Loss of appetite
• Night sweats

Diagnosis
A diagnosis of Clear Cell Sarcoma is made based upon a thorough clinical evaluation and pathological evaluation. Clear cell sarcoma tumors are often imaged by an MRI and CT scan. Biopsy is done to check, if the tumor is Clear Cell Sarcoma. Genetic testing confirm the diagnosis of Clear Cell Sarcoma.

Treatment
Therapies that are used to treat individuals with Clear Cell Sarcoma includes surgery, radiation therapy, chemotherapy and targeted therapy. Two FDA approved chemotherapies used in the management of soft tissue sarcomas are ifosfamide and doxorubicin. The most promising experimental strategies for treating clear cell sarcoma are targeted therapies, which are designed to target specific features of cancer cells. One type of targeted therapy is a receptor tyrosine kinase inhibitor, which blocks overactive signaling molecules in cancer cells that promote cancer growth.

Clear Cell Sarcoma Emerging Drugs Chapters

This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Clear Cell Sarcoma Emerging Drugs

TSR-042: Tesaro TSR-042 is an investigational anti-programmed death (PD)-1 immunotherapy agent. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The therapy is currently under Phase II evaluation in Advanced Clear CellSarcoma.

CPI-613®: Rafael Pharmaceuticals CPI-613® (devimistat) is a ketoglutarate dehydrogenase complex and Pyruvate dehydrogenase complex inhibitor. These are the enzymes of TCA cycle, an indispensable process essential to tumor cell multiplication and survival, selectively in cancer cells. CPI-613® is being evaluated in Phase I clinical studies in combination with hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.

Clear Cell Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Clear Cell Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Clear Cell Sarcoma

• There are approx. 6+ key companies which are developing the therapies for Clear Cell Sarcoma. The companies which have their Clear Cell Sarcoma drug candidates in the most advanced stage, i.e. phase II include, Tesaro.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Clear Cell Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Clear Cell Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Clear Cell Sarcoma.

• In December 2021, Rafael Pharmaceuticals announced that it partners with Sara’s Cure and SARC for the launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in combination with Hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.

Clear Cell Sarcoma Report Insights

• Clear Cell Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Clear Cell Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Clear Cell Sarcoma drugs?
• How many Clear Cell Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Clear Cell Sarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Clear Cell Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Clear Cell Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tesaro
• NantPharma
• Rafael Pharmaceuticals
• Pfizer

Key Products

• TSR-042
• AMG 337
• CPI-613
• Crizotinib

This product will be delivered within 2 business days.